Their observation of higher levels of PD-L1 positive macrophages in lesions from patients with mutant ER metastatic lesions compared to those with WT ER, led to the proposal of greater susceptibility of ER mutant metastatic breast cancer to immunotherapies. Here, ESR1 is linked to breast carcinoma.